Targeting IL-6 in cholangiocarcinoma therapy

Justin L. Mott, Gregory J. Gores

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations


In this issue of the Journal, Cheon and coworkers have examined the utility of serum IL-6 values as a biomarker for cholangiocarcinoma (CCA). Serum IL-6 values were increased in patients with CCA as compared to controls or patients with hepatocellular carcinoma. IL-6 levels also correlated with tumor thickness (a surrogate for tumor burden) as examined by intraductal ultrasonography, a novel approach for assessing CCA tumor burden. Following photodynamic therapy, serum IL-6 values decreased. This study suggests IL-6 may be a biomarker for CCA, confirms the efficacy of photodynamic therapy (PDT) as an antineoplastic therapy, and implies that targeted IL-6 therapy may be beneficial in CCA.

Original languageEnglish (US)
Pages (from-to)2171-2172
Number of pages2
JournalAmerican Journal of Gastroenterology
Issue number10
StatePublished - Oct 2007

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology


Dive into the research topics of 'Targeting IL-6 in cholangiocarcinoma therapy'. Together they form a unique fingerprint.

Cite this